EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Individualized Prediction for Risk of Recurrence in Stage I/ II Melanoma Patients With Negative Sentinel Lymph Node

Shu-Ching Chang iD, Kristel Lourdault iD, Gary L Grunkemeier, Douglas A Hanes, Shih-Ting Chiu, Stacey Stern, Richard Essner

Cancer Medicine · 2024

DOI: 10.1002/cam4.70441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Shu-Ching Chang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Providence St. Joseph Health, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Melanoma, Neoplasm Staging, Neoplasm Recurrence, Local. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the favorable prognosis of AJCC stage I/II melanoma patients, up to 20%–30% will develop metastases. Our objective is to predict long‐term risk (probability) of recurrence in early‐stage melanoma patients.

Methods

A Risk Score to predict long‐term recurrence was developed using Cox regression based on 2668 patients. Five clinicopathological risk factors were included. The association of the Risk Score with the risk of recurrence was evaluated using parametric models (exponential, Weibull, and Gompertz models) and compared to the Cox model using the Akaike information criterion. The discrimination of the model was measured by time‐dependent ROC analyses. A calibration curve was used to evaluate the agreement between predicted and observed recurrence probabilities.

Results

The bootstrap adjusted C‐index was 0.76 (95% CI, 0.74–0.79) overall and 0.87 (0.83–0.90) and 0.82 (0.78–0.85) at one and two years, respectively, and then remained above 0.70 up to 20 years. The Gompertz model for prediction of survival from the Risk Score showed the best performance and displayed good agreement with the Kaplan–Meier curves. The calibration curve of the Gompertz model showed a good agreement between predicted and observed 2‐, 5‐, and 10‐year risk of recurrence. Population‐level analysis demonstrated a significant association of Risk Score with risk of recurrence, with 10‐year risks of recurrence of 4.5%, 13.0%, and 33.7% in the first, second, and third tertiles, respectively.

Conclusion

We developed a Risk Score to predict long‐term risk of recurrence for early‐stage melanoma patients. A Gompertz survival model fit to the Risk Score allows for individualized prediction of time‐dependent recurrence risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNeoplasm StagingNeoplasm Recurrence, LocalHumansFemaleMaleMiddle AgedAgedAdultSentinel Lymph NodePrognosisRisk FactorsRisk AssessmentSkin NeoplasmsProportional Hazards ModelsYoung AdultAged, 80 and overROC CurveKaplan-Meier Estimate

Stichwörter der Autor:innen

Gompertz modelnegative sentinel lymph noderisk of recurrencestage I/II melanoma

Autor:innen und Institutionen

  • Providence St. Joseph Health, Portland, Oregon, USA.
  • Providence Saint John's Cancer Institute, Santa Monica, California, USA.
  • Oregon Health & Science University, Portland, Oregon, USA.

ORCID-Profile: Shu-Ching Chang, Kristel Lourdault

Zitieren

APA

Chang, S. C., Lourdault, K., Grunkemeier, G. L., Hanes, D. A., Chiu, S. T., Stern, S., & Essner, R. (2024). Individualized Prediction for Risk of Recurrence in Stage I/ II Melanoma Patients With Negative Sentinel Lymph Node. Cancer Medicine. https://doi.org/10.1002/cam4.70441

Vancouver

Chang SC, Lourdault K, Grunkemeier GL, Hanes DA, Chiu ST, Stern S, et al. Individualized Prediction for Risk of Recurrence in Stage I/ II Melanoma Patients With Negative Sentinel Lymph Node. Cancer Medicine. 2024. doi:10.1002/cam4.70441

BibTeX
@article{Chang2024,
  author = {Chang, Shu-Ching and Lourdault, Kristel and Grunkemeier, Gary L and Hanes, Douglas A and Chiu, Shih-Ting and Stern, Stacey and Essner, Richard},
  title = {Individualized Prediction for Risk of Recurrence in Stage I/ II Melanoma Patients With Negative Sentinel Lymph Node},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70441}
}
Kostenlos starten →